Takeda Pharmaceutical Company Limited
TAK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,112,796,000 | $1,106,685,000 | $1,053,400,000 | $1,144,124,000 |
| % Growth | 0.6% | 5.1% | -7.9% | – |
| Cost of Goods Sold | $380,061,000 | $384,675,000 | $382,100,000 | $416,874,000 |
| Gross Profit | $732,735,000 | $722,010,000 | $671,300,000 | $727,250,000 |
| % Margin | 65.8% | 65.2% | 63.7% | 63.6% |
| R&D Expenses | $161,482,000 | $143,891,000 | $216,000,000 | $170,193,000 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $253,551,000 | $255,885,000 | $295,900,000 | $270,588,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $248,707,000 | $137,668,000 | $234,300,000 | $219,527,000 |
| Operating Expenses | $663,740,000 | $537,444,000 | $746,200,000 | $660,308,000 |
| Operating Income | $68,995,000 | $184,566,000 | -$74,900,000 | $66,942,000 |
| % Margin | 6.2% | 16.7% | -7.1% | 5.9% |
| Other Income/Exp. Net | -$40,821,000 | -$33,936,000 | -$32,400,000 | -$40,535,000 |
| Pre-Tax Income | $28,174,000 | $150,630,000 | -$107,300,000 | $26,407,000 |
| Tax Expense | $39,903,000 | $26,351,000 | -$4,200,000 | $2,572,000 |
| Net Income | -$11,802,000 | $124,243,000 | -$103,200,000 | $23,789,000 |
| % Margin | -1.1% | 11.2% | -9.8% | 2.1% |
| EPS | -3.74 | 39.7 | -32.62 | 7.51 |
| % Growth | -109.4% | 221.7% | -534.4% | – |
| EPS Diluted | -3.74 | 39.12 | -32.62 | 7.51 |
| Weighted Avg Shares Out | 3,154,932 | 3,129,460 | 3,163,218 | 3,170,000 |
| Weighted Avg Shares Out Dil | 3,154,932 | 3,176,352 | 3,163,218 | 3,170,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44,396,000 | $73,758,000 | $122,988 | $0 |
| Interest Expense | $83,138,000 | $107,158,000 | $330,199 | $207,348 |
| Depreciation & Amortization | $205,155,000 | $181,636,000 | $189,769,000 | $186,955,000 |
| EBITDA | $316,467,000 | $439,424,000 | $181,269,000 | $193,007,000 |
| % Margin | 28.4% | 39.7% | 17.2% | 16.9% |